Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "Use of ctDNA to Complement Tumor Tissue HRR Gene Alteration Testing in TALAPRO-2, A Phase 3 Study of Talazoparib + Enza vs. Placebo + Enza as 1L Treatment for mCRPC"

27 views
June 20, 2023
0 Comments
Login to view comments. Click here to Login
GU